Cible Skin is a shared vision and a medical family legacy.
Founded by Drs. Joël and Raphaël Aknin, Cible Skin pioneers the first true longevity science for the skin.

At the heart of our innovation is 1-LGVTY®, a patented biotechnology born from years of medical expertise and clinical research.

It is the first technology in the world scientifically proven to reduce the skin’s biological age, not just improving appearance, but reversing aging at the cellular level.

By targeting the skin’s immune ecosystem, a master regulator of aging, Cible Skin activates the body’s own mechanisms of regeneration and resilience.

This breakthrough defines a new category at the intersection of medicine, longevity science, and dermatology.

We believe in a future where aging is no longer a decline, but a phase of renewal.

Cible Skin

Org chart

Teams

Offices